All In Biotech

Drug Trial Radar · NCT07842107

Study of Vaccines Against Bundibugyo Virus Disease in Contacts of Cases in the Democratic Republic of the Congo

A Phase 2/3 Randomized, Controlled, Adaptive Platform Trial to Evaluate the Efficacy, Safety, and Immunogenicity of Vaccine Candidates Against Bundibugyo Virus Disease (BVD) in Contacts of Cases

Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 3,620 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

3,620

Planned (sponsor's estimate)

Start

Oct 20, 2026

Primary completion

Apr 2027

Study completion Jun 2027

Sponsor

Lead sponsor
Jean-Pierre Van geertruydenAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Institute of Tropical Medicine, Belgium; Institut National de Recherche Biomedicale (INRB); Epicentre; Médecins Sans Frontières, Belgium; World Health Organization; Coalition for Epidemic Preparedness Innovations
First posted
Sep 25, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 1 year
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Bundibugyo virus (BDBV) causes severe and often fatal outbreaks of Bundibugyo virus disease (BVD). No vaccine against BDBV is licensed. There is an urgent need to identify vaccines that are safe, immunogenic, and effective in preventing disease among people at highest risk of infection. This is a Phase 2/3 randomized, blinded, active-controlled adaptive platform trial evaluating candidate BDBV vaccines in contacts of confirmed BVD cases, co-sponsored by the University of Antwerp and the National Institute of Biomedical Research (INRB), Kinshasa. The contacts of each confirmed index case form a "ring". Eligible contacts are individually randomized to a candidate vaccine or an active comparator on Day 1, and on Day 29 all participants receive the alternative intervention, so that every participant is offered a candidate vaccine while the comparison between groups remains blinded. The platform allows additional candidates to enter as they are prioritized and allows evaluation of a candidate to be discontinued for futility, with an independent Data Monitoring Committee reviewing accumulating data throughout. The overall aim is to generate robust evidence to support the use of BDBV vaccines for outbreak response and future epidemic preparedness.

Conditions

  • Ebola Hemorrhagic Fever
  • Bundibugyo Virus Disease

Interventions

  • Candidate BDBV vaccineBiological

    Candidate Bundibugyo Virus (BDBV) vaccine - A candidate Bundibugyo virus vaccine recommended for prioritization by the independent World Health Organization Technical Advisory Group on Candidate Vaccines Prioritization. Administered as a single dose. Dose, formulation and route are candidate-specific and are specified in the vaccine-specific appendix for each candidate entering the platform. Additional candidate vaccines may be added to the platform as they become available and meet the inclusion criteria.

  • Active comparatorBiological

    Active comparator, Typhoid vaccine. All study interventions are reconstituted and dispensed by an uninvolved third party, such as a trial pharmacist, so that allocation remains masked.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 2: Proportion of participants experiencing serious adverse events, suspected unexpected serious adverse reactions, adverse events of special interest, or medically attended adverse eventsTime frame: Day 1 to Day 181 (+/- 14 days)
  2. Phase 3: Vaccine efficacy against polymerase chain reaction (PCR)-confirmed symptomatic Bundibugyo virus disease with symptom onset 10 to 29 days after vaccinationTime frame: Day 10 to Day 29 after vaccination
  3. Phase 2: Proportion of participants experiencing unsolicited adverse events, Grade 1 to Grade 4Time frame: Day 1 to Day 29 (+/- 2 days); to Day 57 (+/- 2 days) for comparator recipients, timed from their Day 29 vaccination

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Bunia

    Bunia, Ituri, Democratic Republic of the Congo

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.